Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, pharmaceutical products company Taro Pharmaceutical Industries (NYSE:TARO) has earned a respected four-star ranking.

With that in mind, let's take a closer look at Taro and see what CAPS investors are saying about the stock right now.

Taro facts

Headquarters (founded)

Haifa Bay, Israel (1959)

Market Cap

$2.4 billion



Trailing-12-Month Revenue

$688.4 million


Interim CEO James Kedrowski
Interim CFO Michael Kalb

Trailing-12-Month Operating Margin



$479.1 million / $28.3 million


Sandoz International
Teva Pharmaceutical Industries

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 92% of the 50 members who have rated Taro believe the stock will outperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star DrGoldin, succinctly summed up the Taro bull case for our community: "What's not to like? Margins and returns at the high end of the industry, with nothing but consistent growth for the future. All this at a modest p/e (however you wish to calculate it). And clean sheets!"

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.